Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #120 for 2/9/2022

2/8/2022

 
COVID-19 Antibodies and Antivirals
 
An ICER draft review of drugs that are effective to treat the COVID-19 Omicron variant found the risk for hospitalization or death was reduced by 79% with sotrovimab, 30% with molnupiravir and 88% with Paxlovid. A per protocol analysis of fluvoxamine suggested a 66% reduction in the risk for hospitalization. Due to differences in trial population demographics, ICER did not feel the drugs could be compared based on current evidence. All four drugs were found to be cost effective, with a quality-of-life year gained (QALY) < $100,000. The cost of an averted hospitalization was also < $100,000.
 
COVID-19 Antivirals
 
Redhill announced that in a 437 patient, Phase II/III trial (NCT04467840), treatment with opaganib decreased time to viral RNA clearance by at least 4 days compared to placebo in hospitalized patients with severe COVID-19 pneumonia. A subset analysis of 251 patients with an FiO2 of up to 60% found a 62% reduction in mortality. Another subset analysis of 90 patients who were also treated with remdesivir, and corticosteroids found a 70.2% decrease in mortality with the addition of opaganib (6.98% vs 23.4%).
 
S-217622 is a 3CL protease inhibitor, which blocks replication of SARS-CoV-2. Shionogi is evaluating an oral five-day course of S-217622 for the treatment of COVID-19.
  • Shionogi announced that in the Phase IIa portion of a Phase II/III trial, S-217622 decreased viral titers by 60-80% compared to placebo by day four and decreased the time to viral clearance by two days in Japanese patients with mild, moderate, or asymptomatic COVID-19.
COVID-19 Vaccines
 
The CDC agreed with the FDA’s full approval of Moderna’s COVID-19 vaccine and recommend it for patients18 years and older. 
 
At the request of the FDA, Pfizer and BioNTech have submitted a request to expand their COVID-19 vaccine EUA to include children 6 months to < 5 years of age. If approved, this age group would receive two 3 mcg doses. Data to support a third dose given 8 weeks after the second dose is expected to be submitted in the next few months. The vaccine has full approval for patients 16 years and older. An EUA covers use in patients 5 to 15 years. The FDA has scheduled a meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Feb. 15 to discuss the EUA expansion. In anticipation of approval for the vaccine in the patients 6 months to < 5 years of age, the AMA announced the addition of CPT codes to cover this age group.
 
In a 77 patient study, 57% of infants, whose mothers were vaccinated maintained COVID-19 antibody titers, at 6-months, compared to 8% of infants whose mothers had recovered from COVID-19.


Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.